NeuroOne Medical Technologies (NASDAQ:NMTC) Insider Acquires $66,999.33 in Stock

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) insider David Wambeke purchased 33,333 shares of the firm’s stock in a transaction dated Thursday, August 27th. The shares were acquired at an average cost of $2.01 per share, with a total value of $66,999.33. Following the completion of the purchase, the insider directly owned 199,999 shares in the company, valued at approximately $401,997.99. This represents a 20.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

NeuroOne Medical Technologies Stock Down 4.8%

NASDAQ NMTC opened at $1.58 on Friday. The firm’s 50 day moving average is $2.00 and its 200-day moving average is $3.38. The company has a market capitalization of $14.39 million, a PE ratio of -1.66 and a beta of 0.65. NeuroOne Medical Technologies Corporation has a 12-month low of $1.42 and a 12-month high of $6.96.

NeuroOne Medical Technologies (NASDAQ:NMTC) last announced its earnings results on Thursday, August 13th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.07). The business had revenue of $1.97 million for the quarter, compared to analyst estimates of $2.17 million. NeuroOne Medical Technologies had a negative return on equity of 128.12% and a negative net margin of 71.50%. As a group, sell-side analysts expect that NeuroOne Medical Technologies Corporation will post -0.39 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on NMTC shares. Maxim Group set a $5.00 price objective on NeuroOne Medical Technologies and gave the company a “buy” rating in a report on Friday, August 14th. Weiss Ratings lowered NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, NeuroOne Medical Technologies presently has a consensus rating of “Hold” and a consensus price target of $7.33.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Bard Associates Inc. bought a new stake in shares of NeuroOne Medical Technologies in the 2nd quarter valued at about $929,000. Legato Capital Management LLC acquired a new stake in shares of NeuroOne Medical Technologies in the fourth quarter valued at approximately $34,000. XTX Topco Ltd boosted its position in NeuroOne Medical Technologies by 321.1% during the fourth quarter. XTX Topco Ltd now owns 85,454 shares of the company’s stock worth $65,000 after purchasing an additional 65,163 shares during the period. Essex Investment Management Co. LLC bought a new stake in shares of NeuroOne Medical Technologies during the 4th quarter worth about $143,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of NeuroOne Medical Technologies by 10.2% during the fourth quarter. Renaissance Technologies LLC now owns 763,028 shares of the company’s stock worth $578,000 after acquiring an additional 70,428 shares during the period. 16.07% of the stock is currently owned by institutional investors and hedge funds.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.